UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

International journal of molecular sciences, 2018-11, Vol.19 (11), p.3505

2018

Link zum Volltext

Verfügbarkeit prüfen

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2738-2745

2019

Link zum Volltext

Verfügbarkeit prüfen

The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

Human vaccines & immunotherapeutics, 2021-07, Vol.17 (7), p.1935-1939

2021

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review

Frontiers in oncology, 2022-12, Vol.12, p.1023545

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Frontiers in oncology, 2023-02, Vol.13, p.1128569-1128569

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to S. Rossi et al and P. Palassin et al

Journal of clinical oncology, 2023-02, Vol.41 (5), p.1157-1158

2023

Link zum Volltext

Verfügbarkeit prüfen

Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.179-179

2024

Link zum Volltext

Verfügbarkeit prüfen

Characterizing the landscape of RING-type E3 ubiquitin transferase-altered ( RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3134-3134

2023

Link zum Volltext

Verfügbarkeit prüfen

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9120-9120

2023

Link zum Volltext

Verfügbarkeit prüfen

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program

Journal of clinical oncology, 2022-10, Vol.40 (29), p.3439-3452

2022

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2668-2668

2022

Link zum Volltext

Verfügbarkeit prüfen

Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9056-9056

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3157-TPS3157

2022

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics: A primer for clinicians

Blood reviews, 2016-07, Vol.30 (4), p.285-295

2016

Link zum Volltext

Verfügbarkeit prüfen

Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2508-2508

2022

Link zum Volltext

Verfügbarkeit prüfen

Age-associated differences in transcriptional expression and tumor immune microenvironment composition among older patients with cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2633-2633

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.442-442

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.393-393

2022

Link zum Volltext

Verfügbarkeit prüfen

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR -mutant non-small-cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8567-8567

2023

Link zum Volltext

Verfügbarkeit prüfen

Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3126-3126

2023

Link zum Volltext

Verfügbarkeit prüfen

Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2654-2654

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2653-2653

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16617-e16617

2023

Link zum Volltext

Verfügbarkeit prüfen

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.504-504

2023

Link zum Volltext

Verfügbarkeit prüfen

STK11 / TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9087-9087

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(29)
Frontiers In Oncology
(2)
Blood Reviews
(1)
Cancers
(1)
Human Vaccines & Immunotherapeutics
(1)
International Journal Of Molecular Sciences
(1)
The American Journal Of Gastroenterology
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Reply to S. Rossi et al and P. Palassin et al

Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy

Characterizing the landscape of RING-type E3 ubiquitin transferase-altered ( RNF43 alt) colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs)

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials

Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors

Epigenetics: A primer for clinicians

Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada

Age-associated differences in transcriptional expression and tumor immune microenvironment composition among older patients with cancer

Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia

Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis

EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR -mutant non-small-cell lung cancer (NSCLC)

Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines

Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study

Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors

Molecular and immune analysis of adrenocortical carcinoma (ACC): Implications for immune checkpoint inhibition (ICI)

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev)

STK11 / TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile

Aktive Filter

Suchergebnisse filtern